EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan

Sayumi Takahashi iD, Yoichi Kakuta iD, Taku Obara, Tomofumi Ishikawa, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito iD, Rintaro Moroi iD, Hisashi Shiga iD, Nariyasu Mano, Yoshitaka Kinouchi, Atsushi Masamune

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Sayumi Takahashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Pregnancy Complications. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED), JSPS KAKENHI, Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Inflammatory bowel disease (IBD) frequently affects younger patients and poses various challenges concerning pregnancy and childbirth. Maintaining good disease control throughout pregnancy is crucial, but expectant and pregnant patients may worry about the fetal impact of medications, leading to treatment discontinuation due to uncertainty about this issue. This study investigated the real‐world drug‐prescribing practices for pregnant patients with IBD in Japan and their potential connection to major congenital malformations (MCMs).

Methods

Overall, 277 female IBD patients who gave birth between 2010 and 2019 were selected from the JMDC claims database. The prescribing patterns of IBD medications and MCMs in the patients' offspring were analyzed.

Results

Among pregnant IBD patients, 74.4% received at least one medication from 90 days before pregnancy to 90 days after delivery. Trends in medication prescriptions during pregnancy in 2010–2019 revealed consistent use of oral 5‐ASA, variable use of topical medications, a decrease in systemic steroids, and an increase in biologics. The prevalence of MCMs in children born to IBD‐affected mothers did not differ significantly between those who did and did not receive IBD medications (8.6% vs 6.8%). Although circulatory system MCMs were slightly more common in the IBD medication group (4.9% vs 1.4%), this difference was not significant. Logistic regression analysis did not reveal an association between MCM risk and first‐trimester use of IBD medications, including corticosteroids and biologics.

Conclusions

This study provides insights into medication patterns in pregnant IBD patients and suggests no increased risk of MCMs associated with first‐trimester IBD medication use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesPregnancy ComplicationsHumansFemalePregnancyJapanAdultPractice Patterns, Physicians'Abnormalities, Drug-InducedDrug PrescriptionsMesalaminePrevalenceBiological ProductsYoung AdultCongenital AbnormalitiesInfant, NewbornAnti-Inflammatory Agents, Non-Steroidal

Stichwörter der Autor:innen

congenital malformationinflammatory bowel diseasepregnancy

Substanzen

MesalamineBiological ProductsAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Division of Preventive Medicine and Epidemiology, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
  • Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan.
  • Laboratory of Biomolecule and Pathophysiological Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
  • Student Healthcare Center, Institute for Excellence in Higher Education, Tohoku University, Sendai, Japan.

ORCID-Profile: Sayumi Takahashi, Yoichi Kakuta, Takeo Naito, Rintaro Moroi, Hisashi Shiga

Förderung

  • Japan Agency for Medical Research and Development (AMED)
  • JSPS KAKENHI
  • Labour Sciences Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour, and Welfare of Japan
  • Japan Society for the Promotion of Science

Zitieren

APA

Takahashi, S., Kakuta, Y., Obara, T., Ishikawa, T., Nagai, H., Shimoyama, Y., Naito, T., Moroi, R., Shiga, H., Mano, N., Kinouchi, Y., & Masamune, A. (2024). Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16549

Vancouver

Takahashi S, Kakuta Y, Obara T, Ishikawa T, Nagai H, Shimoyama Y, et al. Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16549

BibTeX
@article{Takahashi2024,
  author = {Takahashi, Sayumi and Kakuta, Yoichi and Obara, Taku and Ishikawa, Tomofumi and Nagai, Hiroshi and Shimoyama, Yusuke and Naito, Takeo and Moroi, Rintaro and Shiga, Hisashi and Mano, Nariyasu and Kinouchi, Yoshitaka and Masamune, Atsushi},
  title = {Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16549}
}
Kostenlos starten →